Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Equity Ratio (2022 - 2025)

BioXcel Therapeutics has reported Equity Ratio over the past 4 years, most recently at 2.13 for Q4 2025.

  • Quarterly results put Equity Ratio at 2.13 for Q4 2025, up 12.48% from a year ago — trailing twelve months through Dec 2025 was 2.13 (up 12.48% YoY), and the annual figure for FY2025 was 2.13, up 12.48%.
  • Equity Ratio for Q4 2025 was 2.13 at BioXcel Therapeutics, down from 1.99 in the prior quarter.
  • Over the last five years, Equity Ratio for BTAI hit a ceiling of 0.92 in Q1 2022 and a floor of 4.17 in Q2 2025.
  • Median Equity Ratio over the past 4 years was 0.82 (2023), compared with a mean of 0.95.
  • Biggest five-year swings in Equity Ratio: tumbled 2812.81% in 2024 and later rose 12.48% in 2025.
  • BioXcel Therapeutics' Equity Ratio stood at 0.37 in 2022, then plummeted by 305.57% to 0.77 in 2023, then tumbled by 216.73% to 2.43 in 2024, then rose by 12.48% to 2.13 in 2025.
  • The last three reported values for Equity Ratio were 2.13 (Q4 2025), 1.99 (Q3 2025), and 4.17 (Q2 2025) per Business Quant data.